PADI2 Antibodies

Santa Cruz Biotechnology offers a broad range of PADI2 monoclonal antibodies for various research applications. PADI2 monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). PADI2, or peptidylarginine deiminase type 2, catalyzes the post-translational modification of proteins through citrullination, which influences protein function and interactions. PADI2 has emerged as a significant factor in autoimmune diseases, particularly rheumatoid arthritis, where citrullinated proteins trigger immune responses. Research has shown that PADI2 expression varies across different tissues and cell types, suggesting diverse biological functions. Scientists continue to uncover new roles for PADI2 in both normal physiology and disease states. Understanding PADI2's molecular mechanisms and regulatory pathways provides insights into potential therapeutic targets. PADI2 research using Santa Cruz Biotechnology monoclonal antibodies advances scientific understanding of disease mechanisms and supports the development of new therapeutic strategies.